 |
| Issue 14, 5 December 2007
|
Dear Shareholders
Welcome to the latest edition of Apollo Life, our regular newsletter to keep shareholders informed about our latest developments.
If you would like any further information, please contact us.
Regards
John Priest - CEO |
|
|
|
 |
Apollo launches into Myer with new skincare range
Apollo Applied Science Pty Ltd, the over-the-counter (OTC) marketing division of biopharmaceutical company Apollo Life Sciences, this month launched a unique range of advanced skincare products to be sold in Myer stores throughout Australia.
Apollo's Ellipse Skin Science products use the company's patented Intradel™ nano-technology as well as micro-droplet emulsion and oil / water cream emulsion technologies to provide superior skincare protection and rejuvenation.
Apollo CEO John Priest said the adaptability of Intradel™ will allow Apollo to generate cash flow while the company progresses clinical trials of its needle-free therapeutic drugs which are designed to treat diseases such as psoriasis and rheumatoid arthritis.
"Apollo is continually exploring innovative ways to commercialise its unique topical delivery technologies," said Mr Priest. |
|
|
|
Apollo's oral insulin – key studies completed for trial
Apollo Life Sciences has completed a number of key studies as it prepares to move into the Phase I trial of its oral insulin product.
Apollo CEO John Priest said the company's Oradel™ drug delivery technology had passed a series of pre-trial tests showing the technology has the characteristics needed to protect insulin molecules from the harsh conditions of the gastrointestinal tract and deliver a therapeutic dose of insulin across the wall of the intestine into the bloodstream. |
|
Oradel™ and Intradel™ engines: The "machines" that drive Apollo's product pipeline
At Apollo's recent AGM, CEO John Priest presented a diagram that neatly summarised the company's product pipeline and the technology "engines" (Oradel™ and Intradel™) and "fuel" (human proteins) that drive this pipeline.
"In one simple diagram, investors and analysts can quickly see the links between our technologies and products, how they interact, their stage of development and their market potential," said Mr Priest. |
|
| Click here to subscribe |
 |
| www.apollolifesciences.com |